[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Bechmann LP, Hilgard P, Frilling A, Schumacher B, Baba HA, Gerken G, Zoepf T: Successful photodynamic therapy for biliary papillomatosis: a case report. World J Gastroenterol; 2008 Jul 14;14(26):4234-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful photodynamic therapy for biliary papillomatosis: a case report.
  • Papillomatosis of the bile duct is a rare disease with a high risk of malignant transformation.
  • A previously healthy 65-years old male developed jaundice and right upper abdominal quadrant pain in 1996.
  • A villous adenoma of the distal bile duct was diagnosed.
  • A Whipple procedure was performed.
  • Another adenoma was found in the right hepatic duct resulting in a right hepatectomy.
  • Two years later the patient again developed cholestasis.
  • After drainage of the left hepatic duct with a percutaneous transhepatic cholangial drainage (PTCD) catheter, a recurrent biliary adenomatosis was diagnosed by cholangioscopy.
  • As there was no surgical option left, the patient received photodynamic therapy (PDT) for the recurrent biliary papillomatosis.
  • Three mo after he received further photodynamic therapies, the bile duct epithelium appeared normal and the patient had no signs of adenomatosis, both macroscopically and histologically.
  • The follow-up cholangioscopy in late 2005 revealed only a small papilloma without the need for intervention.
  • In early 2006, the patient died of multi organ failure without signs of extrahepatic cholestasis or cholangitis at the age of 75, 10 years after the diagnosis of biliary papillomatosis was established.
  • Thus, PDT might be a sufficient therapeutic option for recurrent papillomatosis patients with no significant side effects.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Papilloma / drug therapy. Photochemotherapy
  • [MeSH-minor] Aged. Humans. Male

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 Dec;83(12):1715-6 [9038549.001]
  • [Cites] Chirurg. 1996 Jan;67(1):93-7 [8851683.001]
  • [Cites] Gastrointest Endosc. 1997 Sep;46(3):237-43 [9378211.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2005 Jul;15(3):377-97, vii [15990048.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2426-30 [16279895.001]
  • [Cites] Can J Gastroenterol. 2005 Dec;19(12):731-3 [16341314.001]
  • [Cites] Cancer Control. 2001 Jul-Aug;8(4):337-43 [11483887.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(6):542-50 [11180885.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2093-7 [11467637.001]
  • [Cites] J Hepatol. 2001 Oct;35(4):542-3 [11682045.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):763-6 [11726858.001]
  • [Cites] Surg Today. 2003;33(10):781-4 [14513330.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1355-63 [14598251.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(5):390-5 [14598142.001]
  • [Cites] Curr Opin Pulm Med. 2004 Jul;10(4):256-60 [15220748.001]
  • [Cites] Gastrointest Endosc. 2004 Jul;60(1):68-75 [15229428.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Aug;5(4):397-408 [15320770.001]
  • [Cites] Nurs Clin North Am. 1990 Sep;25(3):725-38 [2199943.001]
  • [Cites] Arch Surg. 1991 Jan;126(1):111-3 [1824676.001]
  • [Cites] Aust N Z J Surg. 1997 Sep;67(9):664-6 [9322709.001]
  • (PMID = 18636672.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2725388
  •  go-up   go-down


2. Riojas MA, Guo M, Glöckner SC, Machida EO, Baylin SB, Ahuja N: Methylation-induced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-stage event in colorectal cancer. Cancer Biol Ther; 2007 Nov;6(11):1710-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation-induced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-stage event in colorectal cancer.
  • The hypermethylation of tumor-suppressor gene promoter regions has been shown to result in the epigenetic inactivation of many genes.
  • ASC/TMS1 is a pro-apoptotic gene that has been shown to be methylated in many different human neoplasms.
  • The methylation status of ASC/TMS1 was analyzed in a series of colorectal cancer (CRC) cell lines, adenomas and primary colorectal cancers and normal colorectal tissue samples using methylation-specific PCR (MSP).
  • Methylation analysis showed complete methylation of ASC/TMS1 in 5 of 7 (71%) CRC cell lines.
  • RT-PCR showed absence of mRNA expression in these same cell lines, and expression was restored after treatment with the demethylating drug 5-aza-2'-deoxyazacytidine.
  • The two unmethylated cell lines showed ASC/TMS1 mRNA expression both before and after treatment with 5-aza-2'-deoxyazacytidine.
  • Methylation was seen in 20 of 115 (17%) of primary colorectal cancer specimens, but no methylation was seen in 30 colorectal adenomas and 11 normal colorectal tissue samples.
  • Methylation status of ASC/TMS1 was correlated with a series of clinicopathological variables using multivariate analysis.
  • Methylation of ASC/TMS1 was more common in right-sided tumors (p = 0.02), concordant with hMLH1 methylation (p = 0.03) and is a late stage event, occurring in 0 of 18 tubular adenomas, 0 of 12 villous adenomas, 2 of 44 (5%) Stage 1 cancers, 8 of 31 (26%) Stage 2 cancers, 8 of 21 (38%) Stage 3 cancers and 2 of 19 (11%) Stage 4 cancers.
  • Methylation of ASC/TMS1 appears to be a late-stage event in colorectal carcinogenesis associated with invasive carcinomas but not with normal colorectal tissue or colorectal adenomas.
  • [MeSH-major] Colorectal Neoplasms / genetics. Cytoskeletal Proteins / genetics. DNA Methylation
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986858.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / PYCARD protein, human; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


3. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology; 2002 Mar;122(3):641-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
  • Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment of FAP patients, although long-term use of this therapy has not been studied.
  • We evaluated the long-term effectiveness and toxicity of sulindac in attempting to maintain retained rectal segments free of adenomas.
  • METHODS: Twelve FAP patients (5 women), mean age 37.1 years, with IRA received sulindac (mean dosage, 158 mg/day) for a mean period of 63.4 +/- 31.3 months (range, 14-98 months).
  • Number, size, and histologic grade of polyps, side effects, and medication compliance were assessed every 4 months.
  • Prevention of recurrence of higher-grade adenomas (tubulovillous, villous adenomas) was also observed (P = 0.004).
  • At 35 months of follow-up, 1 patient developed stage III cancer in the rectal stump.
  • CONCLUSIONS: Long-term use of sulindac seems to be effective in reducing polyp number and preventing recurrence of higher-grade adenomas in the retained rectal segment of most FAP patients.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Sulindac / administration & dosage
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Rectum / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874996.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 184SNS8VUH / Sulindac
  •  go-up   go-down


Advertisement
4. Reichart M, Busch OR, Bruno MJ, Van Lanschot JJ: Black esophagus: a view in the dark. Dis Esophagus; 2000;13(4):311-3
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 73-year-old man had a low anterior resection for a villous adenoma in the rectosigmoid.
  • On the 4th day after surgery, he suddenly developed severe interscapular pain.
  • With conservative treatment, including proton pump inhibition, he recovered completely.
  • We hypothesize that a transient gastric outlet obstruction and massive gastroesophageal reflux played a significant role in the etiology of this rare and alarming, but, in this case, completely reversible, syndrome.

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • Hazardous Substances Data Bank. SUCRALFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284980.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors; 54182-58-0 / Sucralfate; KG60484QX9 / Omeprazole
  •  go-up   go-down






Advertisement